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Abstract
Background: Colorectal cancer (CRC) is the secondmost commonmalignant disease and the secondmost common
cause of cancer death in Germany. Official CRC screening starts at age 50. As there is evidence that individuals with a
family history of CRC have an increased risk of developing CRC before age 50, there are recommendations to start
screening for this group earlier. This study aims to evaluate the clinical and economic effects of a risk-adapted
screening program for CRC in individuals between 25 and 50 years of age with potentially increased familial CRC risk.
Methods: FARKOR (Familiäres Risiko für das Kolorektale Karzinom) is a population-based prospective intervention
study. All members of cooperating statutory health insurance companies between 25 and 50 years of age living in a
model region in Germany (federal state of Bavaria, 3.5 million inhabitants in this age group) can participate in the
program between October 2018 and March 2020. Recruitment takes place through physicians and through a public
campaign. Additionally, insurances contact recently diagnosed CRC patients in order to encourage their relatives to
participate in the program. Physicians assess a participant’s familial history of CRC using a short questionnaire. All
participants with a family history of CRC are invited to a shared decision making process to decide on further
screening options consisting of either undergoing an immunological test for fecal occult blood or colonoscopy.
Comprehensive data collection based on self-reported lifestyle information, medical documentation and health
administrative databases accompanies the screening program. Longterm benefits, harms and the cost-effectiveness
of the risk-adapted CRC screening program will be assessed by decision analytic modeling.
(Continued on next page)
*Correspondence: shoffmann@ibe.med.uni-muenchen.de
1Department for Medical information Processing, Biometry, and Epidemiology,
Ludwig-Maximilians University, D-81377 Munich, Germany
Full list of author information is available at the end of the article
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your
intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative
Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
available in this article, unless otherwise stated in a credit line to the data.
Hoffmann et al. BMC Gastroenterology          (2020) 20:131 Page 2 of 9
(Continued from previous page)
Discussion: The data collected in this study will add important pieces of information that are still missing in the
evaluation of the effects and the cost-effectiveness of a risk-adapted CRC screening strategy for individuals under 50
years of age.
Trial registration: German Clinical Trials Register, DRKS-IDDRKS00015097.
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Background
Colorectal cancer (CRC) is the third most commonmalig-
nant disease worldwide, and the second most common
cause of cancer death with many cases occurring in devel-
oped countries [1]. In Germany, more than 60,000 individ-
uals are diagnosed with CRC every year and about 25,000
patients with CRC die, making it the second most com-
mon cancer and the secondmost common cause of cancer
death in Germany [2].
Most cases of CRC develop slowly from precancer-
ous lesions (adenomas). When adenomas or CRC are
detected at an early stage, efficient removal and treat-
ment strategies are available. The possibility to prevent
CRC through early adenoma removal is an advantage
compared to screening and prevention strategies for most
other types of cancer [3–5]. Accordingly, there is growing
evidence from randomized controlled trials and observa-
tional studies that both CRC incidence and CRCmortality
can be reduced through screening followed by preventive
interventions [4, 6–8].
Over the past two decades, a general decline in the inci-
dence and mortality of CRC has been observed in many
countries. At the same time, an increase in CRC incidence
in individuals under 50 years is observed in some countries,
in particular in the United States [9] and Australia [10].
In Germany, current screening recommendations for
the detection of adenomatous polyps and CRC include
biennial testing with an immunological test for fecal
occult blood (iFOBT) for those aged 50 years and older
and colonoscopy every 10 years starting at age 55. How-
ever, about 10% of CRC cases are diagnosed before the age
of 55. Moreover, there is evidence that individuals with a
family history of CRC have a 2- to 4-fold increased risk of
developing colorectal carcinoma [11], resulting in a CRC
incidence similar to that of individuals without a family
history of CRC who are 10 to 15 years older [12]. Despite
recommendations to start CRC screening in this group
before 50 years of age, there are currently no risk-adapted
screening programs for individuals with a family history
of CRC in Germany and in many other countries.
To evaluate a screening program, many aspects have to
be considered [13]: the prevalence of the disease and its
detection rate in the target population, the risks and bur-
dens implied by the program, the risk of overdiagnosis, as
well as aspects of costs. While there are estimates on the
prevalence of CRC and of precancerous lesions in indi-
viduals with a family history of CRC, these estimates may
suffer from an inconsistent treatment of individuals with
hereditary forms of CRC [11, 14, 15]. There are estimates
of the prevalence of having a family history in different
countries and ongoing studies estimating this prevalence
in Germany [16]. Finally, there is evidence concerning
the usefulness of questionnaires to determine family his-
tory of CRC in individuals under 50 years of age [17, 18],
but data on the compliance and the frequency of adverse
effects of CRC screening in a young screening population
are scarce. FARKOR aims to provide the missing infor-
mation to evaluate the clinical and economic effects of
a risk-adapted screening program in individuals between
25 and 50 years of age under real world conditions. This
article describes the original protocol for the FARKOR
(Familiäres Risiko für das Kolorektale Karzinom) study,
a prospective population-based intervention study evalu-
ating the effects of a risk-adapted screening program for
familial colorectal cancer in individuals between 25 and
50 years of age in the federal state of Bavaria (Germany).
Any modifications of the protocol which may impact on
the conduct of the study will require a formal amendment
of the protocol which will be communicated to all relevant
parties.
Aims and objectives
The study evaluates the effects of the risk-adapted screen-
ing program FARKOR, which aims to identify individuals
between 25 and 50 years with a family history of CRC and
to provide effective, safe and cost effective screening mea-
sures for this risk group. In particular, it aims to answer
the following primary research question:
• Does the prevalence of CRC and of advanced
adenoma in the selected risk group justify the use of
the proposed screening measures?
Moreover, the study will address the following secondary
research question:
Hoffmann et al. BMC Gastroenterology          (2020) 20:131 Page 3 of 9
• Does the introduction of a risk-adapted screening
program for individuals between 25 and 50 years lead
to a decrease in CRC mortality in this age group?
Finally, secondary research objectives are:
• To assess the complication rate of screening
colonoscopies in individuals between 25 and 50 years
of age with a family history of CRC
• To evaluate the compliance of a risk-adapted
screening program in the target population by
estimating participation rates depending on region,
patient characteristics and recruitment by medical
specialties
• To assess the long-term incremental effectiveness
and cost effectiveness of FARKOR based on
decision-analytic modeling
Methods/Design
A prospective, population-based intervention study
design was chosen to evaluate the effects of FARKOR. All
participants will give written informed consent prior to
study entry. Recruitment starts in October 2018 and runs
until the end of March 2020. First results are expected to
be available in October 2020.
Participants
The recruitment of participants is multimodal. Partici-
pating statutory health insurance (SHI) companies1 will
inform all patients who have been diagnosed with CRC
in the last 18 months that their relatives may have a
higher risk of developing CRC compared to the gen-
eral population. The recently diagnosed CRC-patient
can inform his/her relatives about the participation in
FARKOR. Moreover, physicians will be able to certify for
the FARKOR program by undergoing a specific internet
based training program on the identification of individ-
uals with a family history of CRC. As FARKOR physi-
cian, they recruit subjects between 25 and 50 years
of age to participate in the screening program. Finally,
there will be a public campaign for the program as well
as a website (https://www.darmkrebs-in-der-familie.de/),
which allows interested individuals to choose a close-by
FARKOR physician.
Inclusion criteria are: Age between 25 and 50 years,
membership of a participating SHI, residence in Bavaria,
and written informed consent. Individuals for whom ade-
quate CRC related screening measures already exist are
1Germany has a two-tier healthcare insurance system. Statutory health
insurance (SHI) is mandatory for employees with incomes below the
contribution assessment ceiling of 56.250 euros per year. The principles of the
SHI system are solidarity and self-governance [19]. Contributions to
not-for-profit SHI sickness funds are provided mutually by employees and
employers. Self-employed citizens and employees with incomes above the
contribution assessment ceiling are allowed to opt out of the system in favor
of private health insurance companies.
excluded from the study. Exclusion criteria are: Previ-
ous diagnosis of CRC, familial adenomatous polyposis or
chronic inflammatory bowel diseases (ulcerative colitis,
Crohn’s disease) or a known family history of hereditary
non-polyposis colorectal carcinoma (HNPCC).
The FARKOR screening process
Participants will be invited by participating physicians to
participate in a short standardized interview regarding
their family history, which is based on a simplified ver-
sion of the Amsterdam and Bethesda criteria [20], and to
sign a written informed consent form. Based on this short
interview consisting of five simple questions concerning
the diagnosis of CRC in first- and second-degree relatives,
participants are either classified as potential risk carrier if
they indicate having at least one first- or second-degree
relative with CRC or as risk free. In a shared decision-
making, potential risk carriers and their physicians discuss
the risks and benefits of possible CRC screening options,
which consist of an iFOBT, a screening colonoscopy, or
deferring further CRC screening measures to a later point
in life. Patients with a positive iFOBT result will undergo
diagnostic workup by colonoscopy and both diagnostic
and screening colonoscopies are accompanied by a com-
prehensive documentation of both macroscopic and his-
tologic findings and of potential complications. In case
of pathologic findings, patients will receive treatment
according to the established guidelines [21]. Additionally,
potential risk carriers will be encouraged to undergo an in-
depth interview regarding their family history of CRC in
which detailed information concerning age, incidence and
mortality of CRC in all first- and second-degree relatives
is ascertained.
The full FARKOR process is shown in Fig. 1 and con-
sists of the following steps: (1) informed consent, (2)
short questionnaire on family history of CRC, (3) shared
decision making, (4) offer to complete an in-depth ques-
tionnaire on family history of CRC, and (5) further screen-
ing measures (iFOBT, colonoscopy, deferral and timing
of future screening procedures). All steps in this screen-
ing process are accompanied by an internet-based doc-
umentation which will be completed by the physicians
participating in the program.
Additionally to this FARKOR screening process, all
participants (with and without family history of CRC)
will be invited to complete an online lifestyle question-
naire based on an instrument previously developed for
the RAPS study (Risiko-adaptierte Präventions-Strategien
für Darmkrebs) [16]. It consists of questions on pre-
existing conditions, participation in prevention programs,
lifestyle habits (e.g. smoking, alcohol consumption, nutri-
tion, exercise, drug use. . . ) as well as anthropometric and
sociodemographic information (including age, sex, height,
weight, and educational level).
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Fig. 1 FARKOR screening process
Data collection and data protection
The data collection consists of (1) an internet-based doc-
umentation of interviews, results of the shared decision-
making, and findings of the proposed screening measures,
(2) an internet-based lifestyle questionnaire, which is self-
administered by the participants, and (3) health insurance
data on the incidence of colorectal adenoma and CRC in
Bavaria between the years 2015 and 2020. A central trust
center will be performing data linkage and pseudonymiza-
tion. It will also coordinate all requests from participants
regarding transparent information, communication and
modalities for the exercise of the rights of the data subject
according to the EU General Data Protection Regulation
(GDPR) including the right to erasure. The analysis will
use anonymized data. The analysis dataset will be stored
for 10 years following the guideline of good epidemiologi-
cal practice (GEP) [22].
Statistical analysis
Primary endpoint
The prevalence of CRC (excluding carcinoma in situ) and
of precancerous lesions will be evaluated in participants
who underwent a screening colonoscopy. Based on health
insurance records, it will also be possible to estimate
the incidence of CRC and of precancerous lesions (1) in
FARKOR participants with familial CRC risk who decide
to defer CRC screening measures to a later point in life
(2) in FARKOR participants who are classified as risk free,
and (3) in individuals in the target population who do not
participate in the FARKOR study.
Secondary endpoint
The number of complications arising through screening
colonoscopies performed in FARKOR will be considered
as secondary endpoint.
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Comparing the prevalence of CRCandof precancerous lesions
in study participants to a general screening population
In order to answer the primary research question, the
prevalence of CRC and of precancerous lesions in study
participants who undergo colonoscopy will be compared
to the findings in a screening population of individu-
als for whom CRC screening is already implemented
in Germany. In particular, the findings concerning the
prevalence of CRC and of clinically relevant precancer-
ous lesions (advanced adenoma, defined as adenoma ≥
10 mm, containing high-grade dysplasia, or villous his-
tology) for colonoscopies performed in FARKOR will be
compared to the prevalence observed in screening colono-
scopies which are proposed to individuals who are aged 55
years and older in Germany.
Modeling long-term outcomes and estimating long-term
effects
Due to its short duration of only 18 months (October
2019 until March 2020), the study cannot provide direct
evidence concerning the effect of a risk-adapted screen-
ing program on CRC mortality in the target population
of individuals between 25 and 50 years of age. Therefore,
CRCmortality will be estimated indirectly based on infor-
mation on the stages of detected CRC cases and on the
characteristics of precancerous lesions in both FARKOR
participants and in individuals in the target population
who do not participate in the screening program. A base-
line estimate of CRCmortality in the target population for
a time period in which no risk-adapted screening was pro-
posed will be estimated based on health insurance data
collected in the three years before the start of the FARKOR
study.
A hierarchical model describing the long-term out-
comes of the FARKOR program is presented in Fig. 2.
The unknown parameters in this hierarchical model can
be estimated through Bayesian inference. In order to pro-
vide more precise estimates and to reduce some of the
uncertainties, it is important to consider not only the
direct sources of information (the study database and the
health insurance data) but also data from indirect sources
of information to make use of all relevant information.
Thus, data from the RaPS study [16], the Munich Cancer
Registry, the Bavarian Cancer Registry, and the scien-
tific literature will be considered as indirect sources of
information.
A detailed description of all statistical methods is pro-
vided in a statistical analysis plan, which will be published
before the end of data collection.
Finally, additional parameters will be evaluated, includ-
ing the number of complications due to performed
colonoscopies, participation rates as a function of region,
patient characteristics and the medical specialties of the
recruiting physicians, and the positive predictive value of
the iFOBT in individuals between 25 and 50 years of age
with a family history of CRC.
Economic evaluation
The systematic evaluation of long-term health-economic
consequences of CRC screening in the population of inter-
est uses a decision-analytic state-transitionmodel [23, 24].
The model reflects the German health care context. It
simulates the natural history of colorectal adenoma and
cancer development in the target population and assesses
the impact of different CRC screening strategies includ-
ing iFOBT and colonoscopy with diagnostic follow-up and
treatment.
The decision model will be applied and calibrated to
the German epidemiological setting using the data of the
Bavarian Cancer Registry and other German cancer reg-
istry data sources. Direct medical costs for screening pro-
cedures, diagnostic tests, treatment and follow-up as well
as resource utilizations are documented within FARKOR.
Outpatient costs will be based on the ’Standardized Rating
Scale of the Federal Association of Physicians under the
Statutory Health Insurance’ and the ’Statutes of Medical
Fees’. Inpatient costs will be derived based on the German
Diagnosis Related Groups System.
The economic analyses use a lifelong time horizon.
The perspective of the German statutory health insur-
ance (SHI) will be adopted and a 3% annual discount
rate will be applied to costs and health outcomes. Out-
comes for benefits and harmswill include life-years gained
(LYG), CRC cases and CRC-related deaths averted, addi-
tional complications due to colonoscopy (physical harm)
and positive test results (psychological harm). Economic
outcomes will include lifetime costs and discounted incre-
mental cost-effectiveness ratios (ICER). Comprehensive
sensitivity analyses assess the uncertainty of the results.
The modeling process follows the guidelines of health
technology assessment (HTA) and comparative effec-
tiveness research. The analysis will comply with inter-
national guidelines and recommendations for decision-
analytic modeling, such as the Joint Task Force guide-
lines of the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) and Society for Medi-
cal Decision Making (SMDM) [24, 25], international key
principles for HTA , reporting guidelines (CHEERS) and
the EUnetHTA guideline for health economic evaluations
[26–29].
The decision-analytic state-transition cohort model will
be programmed and validated using the decision-analytic
software package TreeAge Pro 2017 (TreeAge Software
Inc., Williamstown, MA, USA).
Sample size considerations
The statistical analysis will use a population-based data
set. In the sample size consideration, it is only possible to
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Fig. 2 Schematic representation of statistical modeling: The variables for which information is available for the target population (i.e. all SHI members
between 25 and under 50 years living in Bavaria) are marked in squares and the variables for which there are uncertainties or missing values for at
least part of the target population are marked in circles. The CRC mortality in the study population is shown in blue (left panel) if a risk-adjusted
colorectal cancer screening is offered in Bavaria for people with a family history of colorectal cancer between the age of 25 and under 50 years. The
CRC mortality in the study population is shown in orange (right panel) if no risk-adjusted colorectal cancer screening is offered for this risk group
use educated guesses for specific parameters (see Fig. 3).
The intervention is implemented in a population of about
3.5 million people (Bavarian population between 25 and
50 years of age) of which about 90% (3.15 million people)
are SHI members, who represent the target population.
Health care statistics show that about 1.5 million individ-
uals in the target population get in contact with a prac-
titioner or a CRC screening related physician every year.
We expect that 90,000 (6% of the 1.5 million) will accept
to participate in the program and that 6% of these 90,000
will report a positive family history of CRC. This leads
to 5,400 potential risk carriers recruited through contact
with physicians. Based on the number of CRC cases in
Bavaria, it can be estimated that a further 3,200 potential
risk carriers will be recruited through their first-degree
relatives who are contacted by their SHI. This results in an
expected total of 8,600 participants with a family history
of CRC. About 40% will decide for a colonoscopy (3,440).
The remaining 60% of these subjects will decide for an
iFOBT (5,160) of whom 30% will be positive an undergo
colonoscopy (1,548). It is expected that 33% of the colono-
scopies will produce findings that result in polypectomy
and histology (1,150). Given these numbers, we expect to
be able to calculate confidence intervals of fair precision
for prevalence of CRC or advanced adenoma (±0.01).
Discussion
The Bavarian population of 13 million represents about
16% of the German population. The target population of
this study consists of 3.5 million people. We expect to
perform about 5000 colonoscopies after shared decision-
making of doctors and study participants who are pres-
elected based on a short questionnaire on family history
of CRC. It is of interest to see if the prevalence of CRC
and of precancerous lesions corresponds to the findings
in a screening population of individuals for whom CRC
is already implemented in Germany. About 10% of partic-
ipants in the Bavarian CRC colonoscopy screening pro-
gram (regularly starting at the age of 55 years) present
with advanced adenoma or CRC [30].
Bavaria has also a full coverage by epidemiologic cancer
registries. For the target population the registry reports
2065 CRC cases (ICD10 C18-C21) between 2011 and
2014, corresponding to roughly 500 cases per year. It is of
specific interest if the selection process via simple ques-
tions about the familial colorectal cancer risk is able to
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Fig. 3 Participant flowchart in the FARKOR program
find a relevant part of these affected persons. We assume
to recruit 8600 individuals who are classified as poten-
tial risk carriers in FARKOR. This number is sufficient to
allow precise estimates of the prevalence of CRC and of
precancerous lesions and to assess essential aspects of the
efficacy of the FARKOR screening approach.
It was not possible to implement a comprehensive and
systematic process analysis of the program, which could
have addressed the following questions in detail: What are
facilitators or inhibitors to perform a familial CRC risk
assessment? What are reasons that motivate young adults
with established familial risk to refuse further active pre-
vention steps like iFOBT or colonoscopy? However, we
will address these questions by collecting data concern-
ing a set of potential facilitators and inhibitors including
region, medical specialties, and lifestyle factors.
If FARKOR is able to show that the risk-adapted screen-
ing program is effective or even cost-effective, there is
the option to make it available in whole Germany and to
provide a first risk-adapted approach to a familial CRC
screening.
Currently, there is a further CRC screening approach
provided in the federal states of Berlin and Brandenburg
which is called “Männer, last die Hosen herunter” (“Pants
down, men”). This program motivates men between 40
and 50 years of age to participate in early CRC screen-
ing. It was shown that men have the same risk patterns
regarding advanced adenoma findings about 10 years ear-
lier than women [31]. Furthermore, there is evidence that
men are more reluctant in the participation in screening
programs and do need specific incentives [32].
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